Synopsis
Synopsis
0
EU WC
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Alpha Heparin
2. Alpha-heparin
3. Heparin
4. Heparin Sodium
5. Heparin, Sodium
6. Heparin, Unfractionated
7. Heparinic Acid
8. Liquaemin
9. Unfractionated Heparin
1. (2s,3s,4r,5r,6r)-6-{[(2s,3s,4s,5r,6s)-6-{[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic Acid
2. Hepflush
3. Chembl526514
4. Gtpl4214
5. S01xa14
6. Bdbm50480251
7. (2s,3s,4r,5r,6r)-3-[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2s,3s,4s,5r,6s)-6-[(2r,3s,4s,5r)-2-carboxy-4,6-dihydroxy-5-sulfooxyoxan-3-yl]oxy-2-hydroxy-4-(sulfomethyl)-5-sulfooxyoxan-3-yl]oxy-4,5-dihydroxyoxane-2-carboxylic Acid
1. 9005-49-6
| Molecular Weight | 1039.9 g/mol |
|---|---|
| Molecular Formula | C26H41NO34S4 |
| XLogP3 | -10.4 |
| Hydrogen Bond Donor Count | 14 |
| Hydrogen Bond Acceptor Count | 34 |
| Rotatable Bond Count | 18 |
| Exact Mass | 1039.0392821 g/mol |
| Monoisotopic Mass | 1039.0392821 g/mol |
| Topological Polar Surface Area | 589 Ų |
| Heavy Atom Count | 65 |
| Formal Charge | 0 |
| Complexity | 2140 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 19 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Heparin sodium |
| Drug Label | Intravenous solutions with heparin sodium (derived from porcine intestinal mucosa) are sterile, nonpyrogenic fluids for intravenous administration. They contain no bacteriostat or antimicrobial agent or added buffer. Edetate disodium, anhydrous is ad... |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 5,000 units/ml; 10,000 units/ml; 20,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Hospira; Shenzhen Techdow; Sandoz; Pfizer; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Heparin sodium |
| Drug Label | Intravenous solutions with heparin sodium (derived from porcine intestinal mucosa) are sterile, nonpyrogenic fluids for intravenous administration. They contain no bacteriostat or antimicrobial agent or added buffer. Edetate disodium, anhydrous is ad... |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 5,000 units/ml; 10,000 units/ml; 20,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Hospira; Shenzhen Techdow; Sandoz; Pfizer; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms |
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-26
Pay. Date : 2014-04-03
DMF Number : 7944
Submission : 1989-03-02
Status : Active
Type : II
Registration Number : 218MF10052
Registrant's Address : 12150 Best Place Cincinnati, OH 45241-1569, U.S. S. A.
Initial Date of Registration : 2006-01-27
Latest Date of Registration :
NDC Package Code : 57262-378
Start Marketing Date : 2022-12-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-05-09
Pay. Date : 2013-04-26
DMF Number : 17838
Submission : 2004-11-03
Status : Active
Type : II
Registration Number : 302MF10020
Registrant's Address : C/Antic Cami de Tordera, 109-119, Palafolls, 08389 Barcelona, Spain
Initial Date of Registration : 2020-01-31
Latest Date of Registration :
NDC Package Code : 53484-001
Start Marketing Date : 2009-08-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9472
Submission : 1991-12-23
Status : Inactive
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
NDC Package Code : 60870-0473
Start Marketing Date : 2021-11-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-09-15
Pay. Date : 2020-09-14
DMF Number : 2712
Submission : 1976-08-03
Status : Active
Type : II
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
Registration Number : 222MF10218
Registrant's Address : 12150 Best Place Cincinnati, OH 45241-1569, U.S. S. A.
Initial Date of Registration : 2010-08-10
Latest Date of Registration :
NDC Package Code : 57262-370
Start Marketing Date : 2018-10-22
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-26
Pay. Date : 2014-04-03
DMF Number : 7944
Submission : 1989-03-02
Status : Active
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31738
Submission : 2017-05-17
Status : Active
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26680
Submission : 2013-01-07
Status : Active
Type : II
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
GDUFA
DMF Review : Complete
Rev. Date : 2013-05-09
Pay. Date : 2013-04-26
DMF Number : 17838
Submission : 2004-11-03
Status : Active
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9472
Submission : 1991-12-23
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-09-15
Pay. Date : 2020-09-14
DMF Number : 2712
Submission : 1976-08-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1007
Submission : 1966-11-01
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1622
Submission : 1970-11-19
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1948
Submission : 1972-06-09
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2440
Submission : 1975-03-25
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Sodium, Potency Not Less Than 150 IU/mg ...
Certificate Number : R0-CEP 2004-080 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2005-08-03
Type : Chemical
Substance Number : 333

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2002-043 - Rev 01
Status : Expired
Issue Date : 2005-03-02
Type : TSE
Substance Number : 333

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2002-044 - Rev 01
Status : Expired
Issue Date : 2005-03-02
Type : TSE
Substance Number : 332

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Sodium, Potency Not Less Than 180 IU/mg ...
Certificate Number : R1-CEP 2001-445 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2011-03-30
Type : Chemical
Substance Number : 333

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Sodium, For Parenteral Preparations, Eur...
Certificate Number : R1-CEP 2001-446 - Rev 03
Status : Valid
Issue Date : 2020-02-21
Type : Chemical
Substance Number : 333

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Calcium, For Parenteral Preparations
Certificate Number : CEP 2007-211 - Rev 05
Status : Valid
Issue Date : 2024-07-31
Type : Chemical and TSE
Substance Number : 332

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Sodium, For Parenteral Preparations
Certificate Number : CEP 2004-165 - Rev 06
Status : Valid
Issue Date : 2025-04-14
Type : Chemical
Substance Number : 333

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Sodium, Potency Not Less Than 180 IU/mg ...
Certificate Number : R1-CEP 2001-243 - Rev 01
Status : Valid
Issue Date : 2011-05-03
Type : Chemical
Substance Number : 333

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Heparin Sodium, For Parenteral Preparations
Certificate Number : R1-CEP 2003-192 - Rev 05
Status : Valid
Issue Date : 2023-07-21
Type : Chemical
Substance Number : 333

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
Japanese Pharmacopoeia Heparin Calcium (for manufacturing purposes only)
Registration Number : 222MF10218
Registrant's Address : 12150 Best Place Cincinnati, OH 45241-1569, U.S. S. A.
Initial Date of Registration : 2010-08-10
Latest Date of Registration : 2010-08-10
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
Japanese Pharmacopoeia Heparin Sodium (for manufacturing purposes only)
Registration Number : 218MF10052
Registrant's Address : 12150 Best Place Cincinnati, OH 45241-1569, U.S. S. A.
Initial Date of Registration : 2006-01-27
Latest Date of Registration : 2023-11-22
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
Registration Number : 302MF10020
Registrant's Address : C/Antic Cami de Tordera, 109-119, Palafolls, 08389 Barcelona, Spain
Initial Date of Registration : 2020-01-31
Latest Date of Registration : 2021-10-21
External regulations for heparinoid substances
Registration Number : 305MF10016
Registrant's Address : 1-1 Kano Sakurada-cho, Gifu City, Gifu Prefecture
Initial Date of Registration : 2023-02-02
Latest Date of Registration : 2023-02-02

Registration Number : 231MF10019
Registrant's Address : No. 97,Zhuzhou Road,Laoshan Area,Qingdao,China
Initial Date of Registration : 2019-01-29
Latest Date of Registration : 2019-01-29

Japanese Pharmacopoeia Heparin Sodium
Registration Number : 218MF10198
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigine (Modena) Italy
Initial Date of Registration : 2006-02-08
Latest Date of Registration : 2025-01-23

Registration Number : 217MF11308
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigine (Modena) Italy
Initial Date of Registration : 2005-12-22
Latest Date of Registration : 2024-03-27

Registration Number : 218MF10415
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigin (Modena) Italy
Initial Date of Registration : 2006-04-27
Latest Date of Registration : 2022-11-16

Japanese Pharmacopoeia Heparin Calcium
Registration Number : 223MF10011
Registrant's Address : Via Pacinotti, 3 41043 Corlo di Formigine (Modena) Italy
Initial Date of Registration : 2011-01-21
Latest Date of Registration : 2023-04-05

Heparin-like substance "Roman"
Registration Number : 224MF10084
Registrant's Address : 1-10-4 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa Prefecture
Initial Date of Registration : 2012-04-13
Latest Date of Registration : 2022-10-05

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Meditip Co., Ltd.
Registration Date : 2023-05-19
Registration Number : 20100331-124-G-29-02(10)
Manufacturer Name : Changzhou Qianhong Bio-pharm...
Manufacturer Address : No. 192 Huanghe West Road, Xinbei District, Changzhou, Jiangsu, China

Registrant Name : Sam-O Pharmaceutical Co., Ltd.
Registration Date : 2025-03-17
Registration Number : 20250317-124-G-171-13
Manufacturer Name : Qingdao Jiulong Biopharmaceu...
Manufacturer Address : Jiulong Industry Park, Qingdao, China - 266319

Registrant Name : Medipoem Co., Ltd.
Registration Date : 2026-01-30
Registration Number : 20171016-124-G-150-06(3)
Manufacturer Name : Hebei Changshan Biochemical ...
Manufacturer Address : No.71, Menglong Street, South District of Zhengding High-tech Industrial Development ...

Registrant Name : Iksoo Pharmaceutical Co., Ltd.
Registration Date : 2025-04-07
Registration Number : 20250407-124-G-174-14
Manufacturer Name : Hubei Enoray Biopharmaceutic...
Manufacturer Address : No. 108 Yanjiang Road, Xiaochi Town, Huangmei County, Hubei Province, China

Registrant Name : Medipoem Co., Ltd.
Registration Date : 2025-06-09
Registration Number : 20240717-124-G-172-12(1)
Manufacturer Name : Shenzhen Hepalink Pharmaceut...
Manufacturer Address : No. 1, Rongtian Road, Kengzi Sub-district, Pingshan District Shenzhen City, Guangdong...

Registrant Name : MPK Korea Co., Ltd.
Registration Date : 2024-07-17
Registration Number : 20240717-124-G-172-12
Manufacturer Name : Shenzhen Hepalink Pharmaceut...
Manufacturer Address : No. 1, Rongtian Road, Kengzi Sub-district, Pingshan District Shenzhen City, Guangdong...

Registrant Name : Toru Co., Ltd.
Registration Date : 2023-04-10
Registration Number : 20100211-124-G-17-01(17)
Manufacturer Name : Yantai Dongcheng Biochemical...
Manufacturer Address : No.7,Changbaishan Road, Yantai Development Zone, Shangdong, China

Registrant Name : Nuripharmtech
Registration Date : 2025-12-09
Registration Number : 20100211-124-G-17-01(19)
Manufacturer Name : Yantai Dongcheng Biochemical...
Manufacturer Address : No.7 Changbaishan Road, Yantai Development Zone, Shandong, China

Registrant Name : Korea Chorus Co., Ltd.
Registration Date : 2024-09-09
Registration Number : 20100211-124-G-17-01(18)
Manufacturer Name : Yantai Dongcheng Biochemical...
Manufacturer Address : No.7 Changbaishan Road, Yantai Development Zone, Shandong, China

Registrant Name : Pamire Co., Ltd.
Registration Date : 2026-02-11
Registration Number : 20260211-124-G-175-15
Manufacturer Name : Yino Pharma Limited
Manufacturer Address : 2 Cuiping Erxiang, Yubei District, Chongqing, 401120, China

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
NDC Package Code : 57262-378
Start Marketing Date : 2022-12-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
NDC Package Code : 57262-300
Start Marketing Date : 1988-09-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
NDC Package Code : 57262-370
Start Marketing Date : 2018-10-22
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
NDC Package Code : 53484-001
Start Marketing Date : 2009-08-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0249
Start Marketing Date : 1980-04-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0473
Start Marketing Date : 2021-11-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0467
Start Marketing Date : 2020-03-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52221-123
Start Marketing Date : 2018-12-04
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 51927-0381
Start Marketing Date : 2025-12-09
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 72666-2022
Start Marketing Date : 2022-04-01
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.
About the Company : Smithfield BioScience specializes in harvesting and repurposing porcine‑derived biological materials for pharmaceuticals, medical devices, regenerative medicine, and nutraceutica...
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
About the Company : Bioiberica is a global Life Science company with over 45 years of experience developing & producing high‑value biological molecules for the pharmaceutical and nutraceutical indus...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
About the Company : Pfizer CentreOne® is an altogether different global contract development and manufacturing organization (CDMO), and a leading supplier of specialty APIs and intermediates.
...
About the Company : Shamrock Pharmachemi Pvt Ltd. is a globally recognized API leader with 26+ years in human and veterinary pharmaceuticals. Operating in 40+ countries, it owns two Gujarat facilities...
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
About the Company : Willow Birch Pharma, Inc. is a premier supplier of bulk APIs to North American Compounding Pharmacies, sourcing from FDA registered and GMP manufacturers. With licenses in all 50 s...
About the Company : For more than 45 years, Bacto Chem has stood as a pioneer in the field of bio-pharmaceutical products and formulations. Established in 1972 in Hyderabad, Telangana, by the late D...

About the Company : A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju, who has always thought far ahead of his...

About the Company : HELM Portugal is HELM’s Competence Centre for the marketing of Active Pharmaceutical Ingredients (API). The leading APIs distributed by Helm include Ascorbic Acid pharma Grade (C...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Insulin Glulisine is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): Insulin Glulisine,Insulin aspart,Neutral Protamine Hagedorn Insulin,Glucagon,Glucose,Heparin Sodium
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 22, 2016
Lead Product(s) : Insulin Glulisine,Insulin aspart,Neutral Protamine Hagedorn Insulin,Glucagon,Glucose,Heparin Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insulin Glulisine is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 22, 2016
Details:
Heparin is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pulmonary Embolism.
Lead Product(s): Heparin Sodium,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2025

Lead Product(s) : Heparin Sodium,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Heparin is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pulmonary Embolism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Heparin sodium is an anticoagulant, or "blood thinner," used to prevent and treat blood clots by inhibiting thrombin and other clotting factors via the antithrombin III complex.
Lead Product(s): Heparin Sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Heparin Sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Expands Heparin Sodium Injection Portfolio To Seven Products
Details : Heparin sodium is an anticoagulant, or "blood thinner," used to prevent and treat blood clots by inhibiting thrombin and other clotting factors via the antithrombin III complex.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Catheter-Related Infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections...
Details : Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Catheter-Related Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 12, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Catheter-Related Infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Catheter-Related Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Catheter-Related Infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Catheter-Related Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Immunology Brand Name: Defencath
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces New Commercial Agreement
Details : Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VMX-C001 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.
Lead Product(s): VMX-C001,Rivaroxaban,Heparin Sodium
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VMX-C001,Rivaroxaban,Heparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
Details : VMX-C001 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 24, 2024

Details:
The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: DefenCath
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: CorMedix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2024

Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : CorMedix
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
Details : The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.
Product Name : DefenCath
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 28, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Lead Product(s): Taurolidine,Heparin Sodium
Therapeutic Area: Immunology Brand Name: Defencath
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: ARC Dialysis, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : ARC Dialysis, LLC
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
Details : Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 08, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 9041-08-1
End Use API : Heparin Sodium
About The Company : Suanfarma is a B2B life sciences company focused on developing, manufacturing, and distributing high-quality ingredients for the pharmaceutical industry in an i...
CAS Number : 9041-08-1
End Use API : Heparin Sodium
About The Company : Suanfarma is a B2B life sciences company focused on developing, manufacturing, and distributing high-quality ingredients for the pharmaceutical industry in an i...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
62
PharmaCompass offers a list of Heparin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Heparin Sodium manufacturer or Heparin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Heparin Sodium manufacturer or Heparin Sodium supplier.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, including repackagers and relabelers. The FDA regulates HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER supplier is an individual or a company that provides HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER active pharmaceutical ingredient (API) or HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER finished formulations upon request. The HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers may include HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER API manufacturers, exporters, distributors and traders.
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER DMF (Drug Master File) is a document detailing the whole manufacturing process of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER active pharmaceutical ingredient (API) in detail. Different forms of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER DMFs exist exist since differing nations have different regulations, such as HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER DMF submitted to regulatory agencies in the US is known as a USDMF. HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER USDMF includes data on HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER Drug Master File in Japan (HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER JDMF) empowers HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER JDMF during the approval evaluation for pharmaceutical products. At the time of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER Drug Master File in Korea (HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER. The MFDS reviews the HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER KDMF as part of the drug registration process and uses the information provided in the HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER KDMF to evaluate the safety and efficacy of the drug.
After submitting a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER API can apply through the Korea Drug Master File (KDMF).
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers with KDMF on PharmaCompass.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP of the European Pharmacopoeia monograph is often referred to as a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER Certificate of Suitability (COS). The purpose of a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER to their clients by showing that a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP has been issued for it. The manufacturer submits a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP (COS) as part of the market authorization procedure, and it takes on the role of a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP holder for the record. Additionally, the data presented in the HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER DMF.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER suppliers with NDC on PharmaCompass.
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER GMP manufacturer or HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER GMP API supplier for your needs.
A HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CoA (Certificate of Analysis) is a formal document that attests to HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER's compliance with HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER specifications and serves as a tool for batch-level quality control.
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CoA mostly includes findings from lab analyses of a specific batch. For each HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER may be tested according to a variety of international standards, such as European Pharmacopoeia (HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER EP), HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER JP (Japanese Pharmacopeia) and the US Pharmacopoeia (HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER USP).